What is HC Wainwright’s Forecast for OLMA FY2029 Earnings?

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) – Research analysts at HC Wainwright issued their FY2029 EPS estimates for shares of Olema Pharmaceuticals in a note issued to investors on Wednesday, March 19th. HC Wainwright analyst E. Bodnar anticipates that the company will earn ($2.41) per share for the year. HC Wainwright has a “Buy” rating and a $30.00 price objective on the stock. The consensus estimate for Olema Pharmaceuticals’ current full-year earnings is ($2.33) per share.

Olema Pharmaceuticals (NASDAQ:OLMA) last posted its earnings results on Tuesday, March 18th. The company reported ($0.51) EPS for the quarter, topping the consensus estimate of ($0.63) by $0.12.

Separately, Oppenheimer reaffirmed an “outperform” rating and issued a $25.00 target price (down from $30.00) on shares of Olema Pharmaceuticals in a research report on Wednesday.

Olema Pharmaceuticals Trading Down 0.7 %

NASDAQ:OLMA opened at $4.11 on Thursday. The company has a 50-day moving average price of $5.14 and a 200-day moving average price of $8.43. Olema Pharmaceuticals has a 12 month low of $3.95 and a 12 month high of $16.62. The stock has a market cap of $235.49 million, a price-to-earnings ratio of -1.88 and a beta of 2.11.

Institutional Trading of Olema Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of OLMA. Bain Capital Life Sciences Investors LLC bought a new stake in Olema Pharmaceuticals during the 4th quarter valued at about $43,551,000. Lightspeed Management Company L.L.C. bought a new stake in shares of Olema Pharmaceuticals in the fourth quarter worth approximately $11,257,000. Paradigm Biocapital Advisors LP grew its stake in shares of Olema Pharmaceuticals by 32.7% in the fourth quarter. Paradigm Biocapital Advisors LP now owns 7,304,970 shares of the company’s stock worth $42,588,000 after acquiring an additional 1,801,370 shares during the period. Avoro Capital Advisors LLC bought a new stake in shares of Olema Pharmaceuticals in the fourth quarter worth approximately $9,631,000. Finally, Millennium Management LLC grew its stake in shares of Olema Pharmaceuticals by 1,154.4% in the fourth quarter. Millennium Management LLC now owns 979,219 shares of the company’s stock worth $5,709,000 after acquiring an additional 901,159 shares during the period. 91.78% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other news, major shareholder Bain Capital Life Sciences Inv acquired 300,000 shares of Olema Pharmaceuticals stock in a transaction on Wednesday, January 8th. The stock was acquired at an average cost of $5.76 per share, for a total transaction of $1,728,000.00. Following the purchase, the insider now owns 7,800,000 shares in the company, valued at $44,928,000. This trade represents a 4.00 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 19.40% of the stock is owned by company insiders.

About Olema Pharmaceuticals

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.